Apnimed IPO

apnimed.com

Apnimed, founded in 2017, is a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, MA, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Founded2017
Total Funding to Date$128.27MM
Register for Details

For more details on financing and valuation for Apnimed, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Apnimed Ticker Symbol

Apnimed does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Apnimed Stock Price

The stock price for Apnimed will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Apnimed Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
5/4/2022 Series C-1 and C-2 $62.5MM raised $XXX.XX $XXX.XX
3/25/2021 Series B $25MM raised $XXX.XX $XXX.XX
3/31/2020 Series A-2 $15MM raised $XXX.XX $XXX.XX
6/25/2018 Series A $25.77MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Apnimed in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector